David Liebeskind, MD, FAHA, FAAN, FSVIN, FWSO
UCLA Medical Center
Director, Neurovascular Imaging Research Core
Director, UCLA Comprehensive Stroke Center
More Info & Bio
During this global coronavirus pandemic, I welcome and appreciate the outpouring of effort and heartfelt emotion from so many healthcare providers in our community and beyond. Our society is focused on healthcare delivery and research progress in neurovascular disorders, seemingly far removed from an infectious pandemic, yet the overwhelming impact of this pandemic now extends to so many of us across the world. As the global pandemic evolves from one region to the next, we have witnessed incredible efforts and resourcefulness to limit the spread and impact of COVID-19. From the research labs and medical industry apparatus to the clinical front lines, there has been a groundswell of genuine devotion to a key facet of our mission in healthcare.
Thanks to the pioneering work of my predecessors and close friends, for more than a decade SVIN has served a unique role. In academia, industry and the bedside, SVIN now celebrates numerous accomplishments that we have innovated and established together. MT2020+ is a large initiative and is continuing to grow and find success. Given the nature of the current environment, it is important that we focus attention on next steps in our field rather than laud prior accomplishments. My vision for the coming years in SVIN is to maximally enhance our impact in all spheres of neurovascular and interventional disorders, blurring any potential divisions across disciplines. Beyond SVIN, we seek to work closely in conjunction with other groups, specialists and societies in these endeavors. As part of new initiatives, enriching the diversity of our workforce across all backgrounds and career stages is a key priority.
Ongoing activities at SVIN have benefited from the determined energy of our members. The SVIN Registry continues to track and chronicle the profound impact we have realized in the treatment of acute ischemic stroke with endovascular therapy. We continue to educate and rapidly communicate newfound lessons that affect our stroke and endovascular field. SVIN recently partnered with American Stroke Association to create a new journal titled, Stroke: Vascular and Interventional Neurology. This journal will be online as an Open Access journal and will be released in late 2021. MT2020+continues their campaign to reduce the impact of stroke disability globally. WebNIR Tutorials continue to roll out with great success and large attendance. Thank you to those who have attended monthly. Our social media strategy has bridged interaction especially during the pandemic. The SVIN 2021 Annual Meeting will be held in Phoenix, AZ from November 17-20, check back soon for open registration. I am looking forward to learning, leading, and pursuing our mission into the future. SVIN is a very healthy organization and continues to grow with new members and new opportunities for growth and advancement.
SVIN would like to thank our 2020 Annual Meeting supporters!
Diamond Level Sponsors:
Gold Level Sponsor:
Silver Level Sponsor:
Bronze Level Sponsor:
Thank you for this opportunity to lead SVIN in these challenging times when we can collectively synergize our talents and expertise to achieve the greatest impact.
David S Liebeskind, MD, FAAN, FAHA, FANA, FSVIN, FWSO